PCA
CRL icon

Pallas Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Pallas Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,585
Closed -$2.53M – 607
2024
Q2 		$2.53M Buy
11,585
+647
+6% +$147K 0.11% 135
2024
Q1 		$2.96M Buy
10,938
+5,295
+94% +$1.26M 0.12% 131
2023
Q4 		$1.33M Sell
5,643
-4,441
-44% -$873K 0.07% 175
2023
Q3 		$1.66M Buy
10,084
+415
+4% +$85.2K 0.1% 151
2023
Q2 		$2.02M Buy
9,669
+2,016
+26% +$401K 0.09% 125
2023
Q1 		$1.56M Buy
7,653
+421
+6% +$95.4K 0.15% 106
2022
Q4 		$1.76M Sell
7,232
-57
-0.8% -$12.4K 0.18% 99
2022
Q3 		$1.58M Buy
7,289
+672
+10% +$145K 0.18% 97
2022
Q2 		$1.57M Buy
+6,617
New +$1.62M 0.22% 82
2021
Q4 		– Sell
-729
Closed -$283K – 357
2021
Q3 		$283K Sell
729
-227
-24% -$94.3K 0.03% 316
2021
Q2 		$398K Buy
+956
New +$319K 0.06% 219

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Pallas Capital Advisors's CRL Position: Q3 2024 in Review

Pallas Capital Advisors sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 11,585 shares — an estimated $2.53M sold.

Pallas Capital Advisors first reported a position in CRL in Q2 2021 and held it in 11 quarters. The position peaked at $2.96M in Q1 2024. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Pallas Capital Advisors reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Pallas Capital Advisors sold 11,585 Charles River Laboratories shares in Q3 2024, an estimated $2.53M.
  • Pallas Capital Advisors first reported a position in Charles River Laboratories in Q2 2021 and held it in 11 quarters.
  • Pallas Capital Advisors's Charles River Laboratories position peaked at $2.96M in Q1 2024.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Pallas Capital Advisors's 13F filing for Q3 2024, filed 25 Oct 2024.